Skip to main content
. 2016 Jan 8;23(1):73–77. doi: 10.1128/CVI.00475-15

TABLE 1.

HAI and MN responses to homologous and heterologous H5N1 virus strains with AS03-adjuvanted or nonadjuvanted vaccine

H5 dose (μg) by virus strain Adjuvant used Antibody response (95% CI) by assay ata:
6 mo postvaccination
12 mo postvaccination
n HAI
MN
n HAI
MN
GMT % HAI ≥40 GMT % MN ≥40 GMT % HAI ≥40 GMT % MN ≥40
A/Indonesia/05/2005
    3.75 AS03 42 14.6 (10.8–19.7) 24 (12–39) 70.7 (57.1–87.5) 93 (81–99) 38 8.3 (6.6–10.6) 8 (2–21) 37.2 (28.6–48.4) 58 (41–74)
    3.75 None 25 6.0 (5.1–7.0) 0 (0–14) 12.7 (9.4–17.1) 16 (5–36) 25 5.2 (5.0–5.5) 0 (0–14) 8.2 (6.7–10.1) 0 (0–14)
    7.5 AS03 45 25.4 (18.9–34.1) 44 (30–60) 118.5 (96.0–146.2) 100 (92–100) 39 10.1 (7.7–13.2) 13 (4–27) 57.6 (44.7–74.2) 79 (64–91)
    7.5 None 26 5.0 (–) 0 (0–13) 9.2 (7.5–11.4) 0 (0–13) 24 5.0 (–) 0 (0–14) 7.4 (5.9–9.2) 0 (0–14)
    15 AS03 43 25.5 (18.6–35.0) 53 (38–69) 157.4 (123.5–200.7) 98 (99–100) 41 11.8 (8.9–15.7) 17 (7–32) 79.3 (61.4–102.5) 88 (74–96)
    15 None 24 6.0 (4.9–7.5) 4 (0–21) 17.6 (11.6–26.6) 21 (7–42) 23 5.3 (4.7–6.0) 0 (0–15) 11.1 (7.8–15.9) 9 (1–28)
A/Vietnam/1203/2004
    3.75 AS03 42 7.4 (5.8–9.4) 7 (1–19) 6.8 (6.1–7.5) 0 (0–8) 38 6.3 (5.1–7.9) 3 (0–14) 6.2 (5.6–6.8) 0 (0–9)
    3.75 None 25 5.7 (4.8–6.6) 0 (0–14) 5.2 (5.0–5.5) 0 (0–14) 25 5.6 (4.8–6.5) 0 (0–14) 5.1 (4.9–5.2) 0 (0–14)
    7.5 AS03 45 10.2 (7.8–13.3) 11 (4–24) 8.9 (7.6–10.4) 4 (1–15) 39 7.3 (5.8–9.2) 3 (0–13) 7.0 (5.9–8.3) 3 (0–13)
    7.5 None 26 6.3 (5.1–7.7) 0 (0–13) 5.1 (4.9–5.2) 0 (0–13) 24 5.4 (4.8–6.1) 0 (0–14) 5.1 (4.9–5.2) 0 (0–14)
    15 AS03 43 10.3 (7.7–13.9) 9 (3–22) 10.2 (8.5–12.1) 2 (0–12) 41 7.4 (5.7–9.7) 7 (2–20) 8.5 (7.2–10.1) 0 (0–9)
    15 None 24 6.0 (5.0–7.3) 0 (0–14) 6.0 (5.0–7.2) 0 (0–14) 23 6.6 (5.0–8.7) 4 (0–22) 5.6 (4.8–6.6) 0 (0–15)
A/Anhui/01/2005
    3.75 AS03 42 6.1 (5.3–7.1) 0 (0–8) 46.0 (39.6–53.5) 76 (61–88) 38 5.0 (5.0–5.1) 0 (0–9) 30.1 (24.3–37.4) 50 (33–67)
    3.75 None 25 5.1 (4.9–5.2) 0 (0–14) 13.0 (10.2–16.6) 4 (0–20) 25 5.0 (–) 0 (0–14) 11.0 (9.1–13.3) 0 (0–14)
    7.5 AS03 45 6.8 (5.7–8.1) 2 (0–12) 64.5 (53.8–77.3) 96 (85–99) 39 5.4 (4.9–5.9) 0 (0–9) 38.3 (31.1–47.1) 59 (42–74)
    7.5 None 26 5.0 (–) 0 (0–13) 11.6 (9.1–14.7) 8 (1–25) 24 5.0 (–) 0 (0–14) 8.5 (6.8–10.7) 0 (0–14)
    15 AS03 43 6.7 (5.6–8.0) 2 (0–12) 78.7 (64.6–95.9) 95 (84–99) 41 5.5 (4.9–6.2) 0 (0–9) 52.9 (42.5–65.7) 73 (57–86)
    15 None 24 5.1 (4.8–5.5) 0 (0–14) 16.3 (11.6–23.0) 17 (5–37) 23 5.0 (–) 0 (0–15) 12.0 (8.9–16.2) 9 (1–28)
A/turkey/Turkey/1/2005
    3.75 AS03 42 5.8 (4.9–7.0) 5 (1–16) 33.9 (28.8–40.0) 50 (34–66) 38 5.8 (4.7–7.1) 5 (1–18) 21.7 (17.2–27.3) 34 (20–51)
    3.75 None 25 5.0 (–) 0 (0–14) 8.5 (6.7–10.7) 0 (0–14) 25 5.0 (–) 0 (0–14) 7.0 (5.9–8.2) 0 (0–14)
    7.5 AS03 45 10.7 (7.5–15.2) 24 (13–40) 50.8 (41.6–62.0) 73 (58–85) 39 6.4 (5.1–7.9) 5 (1–17) 30.6 (24.2–38.8) 33 (19–50)
    7.5 None 26 5.7 (4.3–7.5) 4 (0–20) 7.4 (6.2–8.7) 0 (0–13) 24 5.0 (–) 0 (0–14) 5.8 (5.2–6.4) 0 (0–14)
    15 AS03 43 8.2 (6.3–10.8) 9 (3–22) 60.8 (49.6–74.6) 84 (69–93) 41 5.6 (4.8–6.5) 5 (1–17) 37.7 (29.8–47.7) 59 (42–74)
    15 None 24 5.9 (4.2–8.1) 4 (0–21) 11.6 (8.2–16.2) 13 (3–32) 23 5.6 (4.5–6.9) 4 (0–22) 8.3 (6.4–10.9) 4 (0–22)
A/Hubei/1/2010
    3.75 AS03 42 7.6 (5.8–10.6) 14 (5–29) 13.9 (11.5–16.8) 7 (1–19) 38 5.9 (4.6–7.5) 5 (1–18) 10.2 (8.4–12.4) 5 (1–18)
    3.75 None 25 5.8 (4.4–7.8) 4 (0–20) 7.2 (5.9–8.8) 0 (0–14) 25 5.0 (–) 0 (0–14) 6.3 (5.5–7.3) 0 (0–14)
    7.5 AS03 45 7.0 (5.4–9.1) 9 (2–21) 18.2 (15.1–22.1) 18 (8–32) 39 6.0 (4.8–7.4) 5 (1–17) 11.4 (9.2–14.1) 8 (2–21)
    7.5 None 26 5.0 (–) 0 (0–13) 6.7 (5.5–8.2) 0 (0–13) 24 5.0 (–) 0 (0–14) 6.5 (5.5–7.6) 0 (0–13)
    15 AS03 43 6.5 (5.1–8.4) 7 (1–19) 23.3 (18.4–29.5) 21 (10–36) 41 6.2 (4.8–8.1) 5 (1–17) 17.8 (13.3–23.8) 20 (9–35)
    15 None 24 5.3 (4.7–6.0) 0 (0–14) 9.6 (6.7–13.6) 8 (1–27) 23 5.6 (4.8–6.5) 0 (0–15) 7.0 (5.2–9.3) 4 (0–22)
a

95% CI, 95% confidence interval. The presence of a single dash in parentheses indicates that there is no range for the 95% CI.